WorldWideScience

Sample records for buserelin

  1. The effects of buserelin microparticles on ovarian function in healthy ...

    African Journals Online (AJOL)

    The effects of buserelin microparticles on ovarian function in healthy women. B. H. Meyer, F. O. Muller, N. de la Rey, H. G. Luus,. B. Rosenkranz. Objective. To investigate the tolerance, pharmacokinetics and pharmacodynamJcs of the microparticle fonnulation of buserelin, when it wasaaministered subcutaneously. Design.

  2. The effects of buserelin microparticles on ovarian function in healthy ...

    African Journals Online (AJOL)

    The effects of buserelin microparticles on ovarian function in healthy women. B. H. Meyer, F. O. Muller, N. de la Rey, H. G. Luus, B. Rosenkranz. Abstract. Objective. To investigate the tolerance, pharmacokinetics and pharmacodynamJcs of the microparticle fonnulation of buserelin, when it wasaaministered subcutaneously.

  3. The effects of buserelin microparticles on ovarian function in healthy ...

    African Journals Online (AJOL)

    Design. Asingle-blind, randomised, parallel-group design was used to investigate the duration of suppression of ovarian function associated with doses of 1,8, 3,6 and 7,2 mg buserelin administered subcutaneously as ... In another study gonadorelin microcapsules suppressed the pituitary testicular axis for at least 50 days.

  4. Effects of Gonadotropin Releasing Hormone Agonist (Buserelin) on Development of Ovarian Follicles of Adult Rats

    OpenAIRE

    Tahmineh Peirouvi; Hadis Mohammadbeigi

    2016-01-01

    Introduction and Aims Nowadays, GnRH agonist like buserelin acetate was used for treatment of infertility witch causes development of ovarian follicles. The purpose of this study was to investigate effects of buserelin on the follicles development of ovary. Materials and Methods In this experimental interventional study, 24 adult female Wistar rats were randomly divided into 3 groups (n=8). First and second treated groups received 300 μg/kg and 600 μg/kg buserelin for 5 days re...

  5. Acute Transverse Myelitis Associated with Buserelin Use during IVF

    Directory of Open Access Journals (Sweden)

    Djavid I. Alleemudder

    2013-01-01

    Full Text Available A healthy woman undergoing in vitro fertilization (IVF developed acute transverse myelitis (ATM following the use of Buserelin. ATM has a multifactorial etiology and may develop as a result of the activation of immune responses. Infectious agents have been postulated as possible triggers of an immune response (Sá, 2009. Gonadotropin-releasing agonists may have a similar role and trigger the acceleration of preexisting disease by the activation of immune responses (Ho et al., 1995, and Umesaki et al., 1999.

  6. Induction of ovulation with buserelin in jennies: in search of the minimum effective dose.

    Science.gov (United States)

    Camillo, Francesco; Vannozzi, Iacopo; Tesi, Matteo; Sabatini, Chiara; Rota, Alessandra; Paciolla, Elisabetta; Dang-Nguyen, Irene; Panzani, Duccio

    2014-12-10

    The aim of this study was to evaluate the minimum dose of buserelin acetate (buserelin) able to induce ovulation between 24 and 48 h from treatment (positive response) in estrous jennies. Jennies were studied during a total of 172 estrous cycles: ovarian activity was routinely monitored by ultrasound; when the dominant follicle reached a diameter of 33 ± 1 mm, estrous jennies were treated by subcutaneous administration of different doses of buserelin, 3.3mg (N = 11), 1.5mg (N = 21), 0.8 mg (N = 12), 0.4 mg (N = 16), 0.2mg (N = 13), 0.1mg (N = 16), 0.04 mg (N = 14), 0.02 mg (N = 16), or employed as controls (N = 53). Single jennies (P = 0.0001) and GnRH dose (P = 0.003) significantly affected ovulation rates. Ovulation rates between 24 and 48 h of each treated group, except for the 0.02 mg group, was higher than in the control group (P < 0.05). The minimum dose of buserelin effective to induce ovulation in estrous jennies was 0.04 mg. Copyright © 2014. Published by Elsevier B.V.

  7. Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle.

    Science.gov (United States)

    Picard-Hagen, N; Lhermie, G; Florentin, S; Merle, D; Frein, P; Gayrard, V

    2015-07-15

    Analogs of gonadoliberin (GnRH) are widely used in cattle to synchronize estrus and to induce ovulation, as well as for the treatment of ovarian cysts. The aim of this study was to compare the plasma profiles of LH and progesterone and the follicular dynamics in response to the administration of gonadorelin, lecirelin, or buserelin at the dose recommended to induce ovulation. In addition, the biological response to a half dose of lecirelin was assessed. Twelve healthy Holstein female cows were divided into four sequence groups, according to a Latin square design and received the four treatments during the four periods of the study. Before each period, the estrous cycle was synchronized, and on Day 6 or 7 of the ensuing cycle, the time at which it was most likely to have a dominant follicle, 100 μg of gonadorelin, 25 μg of lecirelin, 50 μg of lecirelin, or 10 μg of buserelin was administered to the cows. Blood samples were regularly collected for up to 4 days after the GnRH administrations. The plasma LH response was evaluated for up to 6 hours after administration, and the plasma progesterone response and ovarian follicular dynamics were evaluated for up to 4 days. There was a significantly lower LH release after gonadorelin treatment compared to lecirelin at the doses of 25 or 50 μg and the buserelin treatment. The mean maximal LH concentration after gonadorelin treatment was 2.5 lower than after lecirelin or buserelin treatment and was reached 1 hour earlier. Four days after the GnRH administration (i.e., at Days 10-11 of the estrous cycle), the overall mean increase in plasma progesterone concentration was 70% and did not differ between the treatment groups. The percentage of disappearance of the dominant follicle (84.8% of ovulation and 4.3% of luteinization) after GnRH treatment was high (73%, 82%, 100%, and 100%, for gonadorelin, lecirelin at the doses of 25 and 50 μg, and buserelin, respectively) and did not differ between the GnRH treatments. The

  8. Induction of an LH surge and ovulation by buserelin (as Receptal) allows breeding of weaned sows with a single fixed-time insemination

    NARCIS (Netherlands)

    Driancourt, M.A.; Cox, P.; Rubion, S.; Harnois-Milon, G.; Kemp, B.; Soede, N.M.

    2013-01-01

    The aim of this study was to demonstrate successful breeding of sows with a single fixed-time insemination following ovulation induction by buserelin, a GnRH analogue. In a first step, the optimal dose of buserelin (6, 10, or 16 µg) injected at 77 hours after weaning was determined in weaned sows (N

  9. Fertirelin and buserelin compared by LH release, milk progesterone and subsequent reproductive performance in dairy cows treated for follicular cysts.

    Science.gov (United States)

    Osawa, T; Nakao, T; Kimura, M; Kaneko, K; Takagi, H; Moriyoshi, M; Kawata, K

    1995-10-15

    This field study compared the efficacy of a single injection of 200 microg fertirelin with that of 20 microg buserelin in shortening the recovery period of 68 laotating Holstein-Friesian cows with ovarian follicular cysts 65 d post partum or later. Differential diagnosis was based not only on palpation per rectum but also on skim milk progesterone profiles (cows showed an LH increase four-fold or greater. Luteinization, indicated by progesterone levels (>or= 1.0 ng/ml) 1 wk after treatment, was evidenced in 75% of the fertirelin group and 72% of the buserelin group. A 74% conception rate was achieved in fertirelin-treated cows, with a mean interval of 71 d from treatment to conception. In the buserelin-treated cows, 65% conceived and the treatment-to-conception interval was 63 d. Differences were insignificant. At the doses used the two GnRH analogs were deemed equally effective in managing particularly stubborn follicular cysts.

  10. HALF-DOSE DEPOT TRIPTORELIN COMPARABLE TO REDUCED DAILY BUSERELIN: A RANDOMIZED CLINICAL TRIAL

    Directory of Open Access Journals (Sweden)

    L. Safdarian

    2007-09-01

    Full Text Available Pituitary suppression by depot GnRH agonist may be excessive for ovarian stimulation. This study compares the efficacy of a single half-dose depot triptorelin and reduced-dose daily buserelin in a long protocol ICSI/ET. METHODS: A total of 182 patients were randomized into two groups using sealed envelopes. Pituitary desensitization was obtained in group 1 (91 patients with half-dose (1.87 mg depot triptorelin in the mid-luteal phase of their menstrual cycle, and in group 2 (91 patients with standard daily dose (0.5 mg buserelin, which was then reduced to 0.25 mg at the start of human menopausal gonadotropin (HMG stimulation. RESULTS: No significant differences were found among those who received HCG in terms of clinical pregnancy rate (34.4% in both groups, implantation rate (14.8% in group 1 versus 11.1% in group 2, fertilization rate (93.3 versus 95.6%, poor response rate (11.1 versus 6.7%, and miscarriage rate (11.1 versus 7.8%. No significant differences were seen in number of HMG ampoules used, follicles at HCG administration, and oocytes retrieved. The number of days of stimulation was significantly reduced in group 2 (11.2 +/- 1.8 in group 1 versus 10.6 +/- 1.9, p = 0.030. CONCLUSION: A half-dose of depot triptorelin can be successfully used in ovarian stimulation instead of reduced-dose daily buserelin, with more patient comfort and reduced stress and cost of injections.

  11. Development of [{sup 111}In]-DTPA-buserelin for GnRH receptor studies

    Energy Technology Data Exchange (ETDEWEB)

    Jalilian, A.R.; Akhlaghi, M.; Kamali-Dehghan, M.; Moradkhani, S. [Nuclear Medicine Research Group, Agricultural, Medical and Industrial Research School (AMIRS-NSTRI), Karaj (Iran); Shanehsazzadeh, S. [Dept. of Medical Physics, Tehran Univ. of Medical Sciences (Iran)

    2010-07-01

    Buserelin was successively labeled with [{sup 111}In]-Indium chloride after residuation with DTPA-dianhydride. Radio-chromatography showed an overall radiochemical purity of > 90% (RTLC) and > 95% (HPLC) at optimized conditions after labeling (specific activity: 400-450 GBq/M). The serum stability of the tracer was determined up to 24 h. The biodistribution of the tracer was determined in normal rats showing significant breast and ovaries uptakes 60 min post injection. MCF-7 cell binding of the tracer was > 98%. A significant testes uptake was demonstrated in normal male rats using SPECT studies. (orig.)

  12. Reproductive performance of dairy cows with luteal or follicular ovarian cysts after treatment with buserelin.

    Science.gov (United States)

    Probo, Monica; Comin, Antonella; Mollo, Antonio; Cairoli, Fausto; Stradaioli, Giuseppe; Veronesi, Maria C

    2011-09-01

    In dairy farm management economic losses resulting from cystic ovarian degeneration are well known. In spite of this, neither the definition nor the aetiopathology of ovarian cysts are clear and agreed upon. Also the usual classification in luteal and follicular cysts, requiring ultrasound examination together with assessment of P4 to be accurate, is not very helpful in field conditions. Consequently a single treatment is often provided for both types of cysts, and since the 1970s treatments with GnRH and its analogues have been considered very useful. Nevertheless differences in recovery rates after GnRH treatment in animals with either luteal or follicular cysts are reported. Thus, the aim of this study was to evaluate recovery rate, recovery time and conception rate after treatment with buserelin (GnRH-analogue) in cows with ovarian luteal or follicular cysts. In a 5 years period, 150 cows with cysts out of a total of 990 animals, were detected and treated intravenously between 45 and 60 days PP with 20μg buserelin. No statistically significant differences were found in recovery rates and in conception rates between the two types of cysts. Comparison of recovery times showed significantly shorter recovery for cows with luteal cysts. The results emphasise the usefulness of GnRH to treat ovarian cysts regardless of their type, in relation to both recovery and conception rates. Intervals from treatment to resumption of ovarian activity were affected by the characteristics of ovarian cysts, with a faster recovery for the luteal type. Copyright © 2011 Elsevier B.V. All rights reserved.

  13. Impact of Buserelin Acetate or hCG Administration on the Day of First Artificial Insemination on Subsequent Luteal Profile and Conception Rate in Murrah Buffalo (Bubalus bubalis).

    Science.gov (United States)

    Pandey, A K; Ghuman, Sps; Dhaliwal, G S; Agarwal, S K; Phogat, J B

    2016-08-01

    This study was designed to investigate the impact of buserelin acetate (BA) or human chorionic gonadotropin (hCG) administration on the day of first artificial insemination (AI) on subsequent luteal profile (diameter of corpus luteum (CL) and plasma progesterone) and conception rate in Murrah buffalo. The present experiment was carried out at two locations in 117 buffalo that were oestrus-synchronized using cloprostenol (500 μg) administered (i.m.) 11 days apart followed by AI during standing oestrus. Based on treatment (i.m.) at the time of AI, buffalo were randomly categorized (n = 39 in each group) into control (isotonic saline solution, 5 ml), dAI-BA (buserelin acetate, 20 μg) and dAI-hCG (hCG, 3000 IU) group. Out of these, 14 buffalo of each group were subjected to ovarian ultrasonography on the day of oestrus to monitor the preovulatory follicle and on days 5, 12, 16 and 21 post-ovulation to monitor CL diameter. On the day of each sonography, jugular vein blood samples were collected for the estimation of progesterone concentrations. All the buffalo (n = 117) were confirmed for pregnancy on day 40 post-ovulation. The conception rate was better (p hCG (66.7%) groups as compared to their control counterparts (30.8%). Furthermore, the buffalo of dAI-hCG group had improved (p  0.05) to exhibit stimulatory impact of treatment on luteal profile when compared to control group. In brief, buserelin acetate or hCG treatment on the day of first AI leads to an increase in conception rate; however, an appreciable impact on post-ovulation luteal profile was observed only in hCG-treated Murrah buffalo. © 2016 Blackwell Verlag GmbH.

  14. Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study.

    NARCIS (Netherlands)

    Huirne, J.A.; Hugues, J.N.; Pirard, C.; Fischl, F.; Sage, J.C.; Pouly, J.L.; Obruca, A.; Braat, D.D.M.; Loenen, A.C. van; Lambalk, C.B.

    2006-01-01

    BACKGROUND: The aim of this study was to assess the non-inferiority of an oral contraceptive (OC)-pretreated cetrorelix regimen and a buserelin regimen in IVF/ICSI patients treated with r-hFSH in terms of total number of oocytes retrieved. METHODS: Multicentre, randomized study. One hundred and

  15. Impact of phase of the estrous cycle and season on LH surge profile and fertility in dairy cows treated with different GnRH analogs (gonadorelin vs. buserelin).

    Science.gov (United States)

    Armengol-Gelonch, R; Mallo, J M; Ponté, D; Jimenez, A; Valenza, A; Souza, A H

    2017-03-15

    Our aim was to assess the GnRH-induced LH surge profile in dairy cows receiving two GnRH products (gonadorelin vs buserelin) given at proestrus or diestrus phase and to investigate whether season could alter LH surge profile in dairy cows. In Experiment 1, dairy cows at 108.2 ± 2.3 DIM, producing 41.5 ± 0.3 kg/day were randomized to receive, during proestrus and diestrus: Ovarelin® i.m. (OVA; n = 56; 100 mg of gonadorelin diacetate tetrahydrate; Ceva Animal Health, France) or Receptal® i.m. (REC; n = 52; 10 mcg of buserelin diacetate; MSD, Germany). In Experiment 1, blood samples were collected at hour 0 (just before GnRH treatment) at 30min, 1 h and then hourly until 5 h post-GnRH. In Experiment 2, cows were synchronized with a modified G-6-G protocol and randomized to receive either OVA or REC throughout the synchronization program. In Experiment 1, peak LH concentrations (ng/mL) were not affected by type of GnRH (OVA = 6.2 ± 0.4 vs REC = 6.7 ± 0.4; P = 0.37) or season (Cool = 6.8 ± 0.4 vs Warm = 6.1 ± 0.4; P = 0.22), and there were no interactions between GnRH type and phase of the estrous cycle or season. Interestingly, the area under the curve (AUC) of LH release (ng/ml*time) was significantly lower during warmer months (Cool = 20.3 ± 1.2 vs Warm = 16.9 ± 1.1; P = 0.04). As expected, LH peak was affected by phase of the cycle (proestrus = 8.2 ± 0.4 vs diestrus = 4.7 ± 0.4; P surge profile and cows during warm season had reduced AUC. Additionally, type of GnRH did not influence LH surge profile and P/AI in synchronized cows. Regardless of GnRH type, strategies to avoid heat stress and excessively high levels of circulating P4 near the time of GnRH treatment might help improve LH release profile in dairy cows, and ultimately increase P/AI. Copyright © 2017 Elsevier Inc. All rights reserved.

  16. Sincronização da onda folicular com buserelina prévia à indução da luteólise com cloprostenol em bovinos Follicular wave synchronization with buserelin before the luteolisis induction with cloprostenol in cattle

    Directory of Open Access Journals (Sweden)

    Deiler Sampaio Costa

    1999-01-01

    Full Text Available Este experimento foi realizado para verificar o efeito da aplicação de diferentes doses de um análogo de GnRH (buserelina sobre a emergência de nova onda de crescimento folicular e o número de folículos recrutados dessa onda, a formação de corpo lúteo acessório, o diâmetro do folículo dominante e do corpo lúteo espontâneo no dia da aplicação do luteolítico e subseqüente taxa de sincronização e o intervalo da aplicação de PGF2α à manifestação do estro. Vinte fêmeas bovinas em diestro, mestiças Holandês x Zebu e Simental x Zebu foram, distribuídas em quatro tratamentos contendo cinco animais cada. No tratamento 1, os animais receberam 4 mg IM de buserelina no dia z 0 (dia em que se iniciou o tratamento e 150 mg de D(+ cloprostenol no dia 6. Nos tratamentos 2, 3 e 4, receberam, respectivamente, 6, 8 e 10 mg de buserelina, pela mesma via de aplicação, e 150mg de D(+ cloprostenol no dia 6. A atividade ovariana foi monitorada diariamente, com auxílio do aparelho de ultra-sonografia, do dia 0 ao estro, ou até o dia 11 pós-tratamento, naqueles animais que não responderam à prostaglandina. A aplicação de 8 ou 10 mg de buserelina em fase indeterminada do diestro, nas fêmeas bovinas mestiças, promoveu emergência de nova onda de crescimento folicular mais rápida que aplicações de 4 ou 6 mg do mesmo hormônio; enquanto os outros parâmetros avaliados não diferiram entre os animais dos tratamentos.This experiment was carried out to verify the effect of the administration of different doses of GnRH (buserelin analogue on the emergence of a new follicular growth wave and the number of recruited follicles from this wave, accessory corpus luteum formation, the dominant follicle diameter and the spontaneous corpus luteum on the luteolitic administration day and subsequent synchronization rate and the interval between the PGF2α application and the estrus manifestation. Twenty crossbreed female cattle in diestrus

  17. Desenvolvimento folicular no pós-parto de vacas da raça Gir tratadas com acetato de buserelina (GnRH ou gonadotrofina coriônica humana (hCG Follicular development in Gir breed cows (Bos indicus treated with buserelin acetate or human chorionic gonadotrophin during the postpartum period

    Directory of Open Access Journals (Sweden)

    Álan Maia Borges

    2004-12-01

    Full Text Available Foram utilizadas 22 vacas da raça Gir (Bos indicus em anestro pós-parto, amamentando e mantidas sob regime de pastejo. O padrão de crescimento folicular foi estudado em 15 animais, enquanto os outros sete foram utilizados somente no acompanhamento da resposta aos tratamentos hormonais. Ultra-sonografia em tempo real foi realizada diariamente, do quarto ao qüinquagésimo dia de lactação, por meio de aparelho equipado com probe de 5MHz. Nenhum animal apresentou estro, ovulação ou luteinização folicular durante o período de avaliação. Verificaram-se quatro a oito ondas foliculares surgindo em intervalos de seis a sete dias, cujo diâmetro máximo dos folículos dominantes e subordinados foi de 8,9±0,6 e 6,3±0,7mm, respectivamente. Aos 56 dias pós-parto, as 22 vacas foram divididas em dois grupos: 11 tratadas com 4,2 mig de acetato de buserelina e 11 com 3.000UI de hCG. A ovulação, regressão e luteinização folicular foram verificadas em animais dos dois tratamentos e uma nova onda folicular surgiu dentro de dois a três dias após a terapia hormonal. Corpos lúteos de menor tamanho e concentrações de progesterona abaixo de 1ng/mL indicaram baixa atividade luteal.This experiment was carried out with 22 anestrus Gir cows (Bos indicus, with the postpartum follicular growth studied in 15 of these suckling and kept on pasture, while the seven others were used only for hormonal treatments. Daily real time ultrasonography was done from 4th to the 50th day, using B-mode ultrasound scanner equipped with a linear array 5.0MHz probe. No animal showed estrus, ovulation or follicular luteinization during de experimental period. Four to eight follicular waves emerged each six or seven days and maximum diameter of dominant and subordinate follicles were 8.9±0.6mm and 6.3±0.7mm, respectively. On day 56 of postpartum all cows were separated in two groups: 11 cows were treated either with 4.2 mug of buserelin acetate and 11 with 3,000UI of h

  18. The effects of buserelin microparticles on ovarian function in healthy ...

    African Journals Online (AJOL)

    If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs. Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link ...

  19. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study

    NARCIS (Netherlands)

    J.G.M. Klijn (Jan); M. Piccart; J. Burghouts; L. Duchateau; D. Becquart; F. Mignolet; C.M. Seynaeve (Caroline); L.V. Beex (Louk); L. Mauriac; J.A. van Zijl; C. Veyret; J. Wildiers; J. Jassem

    2000-01-01

    textabstractBACKGROUND: Surgical or medical castration and antiestrogenic treatment with tamoxifen are common endocrine treatments for premenopausal women with breast cancer. However, tamoxifen therapy induces high levels of plasma estradiol, with unknown long-term

  20. Protection of germinal epithelium with luteinizing hormone-releasing hormone analogue

    Energy Technology Data Exchange (ETDEWEB)

    Nseyo, U.O.; Huben, R.P.; Klioze, S.S.; Pontes, J.E.

    1985-07-01

    A dog model for chemotherapy and radiation-induced testicular damage was created to study the protective potential of superactive analogue of luteinizing hormone-releasing hormone, buserelin. Buserelin appeared to offer protection of the canine germinal epithelium against cyclophosphamide, cisplatinum and radiation. Clinical trials with buserelin in patients of reproductive age undergoing treatment for cancer should be encouraged.

  1. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment.

    Science.gov (United States)

    Bixo, M; Allard, P; Bäckström, T; Mjörndal, T; Nyberg, S; Spigset, O; Sundström-Poromaa, I

    2001-08-01

    Changes in serotonergic parameters have been reported in psychiatric conditions such as depression but also in the premenstrual dysphoric disorder (PMDD). In addition, hormonal effects on serotonergic activity have been established. In the present study, binding of [3H]paroxetine to platelet serotonin uptake sites and binding of [3H]lysergic acid diethylamide ([3H]LSD) to platelet serotonin (5-HT)2A receptors were studied in patients with PMDD treated with a low dose of a gonadotropin releasing hormone (GnRH) agonist (buserelin) or placebo and compared to controls. The PMDD patients were relieved of premenstrual symptoms like depression and irritability during buserelin treatment. The number of [3H]paroxetine binding sites (Bmax) were significantly higher in the follicular phase in untreated PMDD patients compared to controls. When treated with buserelin the difference disappeared. No differences in [3H]LSD binding between the three groups were shown. The present study demonstrated altered platelet [3H]paroxetine binding characteristics in women with PMDD compared to controls. Furthermore, [3H]paroxetine binding was affected by PMDD treatment with a low dose of buserelin. The results are consistent with the hypothesis that changes in serotonergic transmission could be a trait in the premenstrual dysphoric disorder.

  2. Comparisons of several dosages of a GnRH analog with the standard dose of hCG in the treatment of follicular cysts in dairy cows.

    Science.gov (United States)

    Nakao, T; Tomita, M; Kanbayashi, H; Takagi, H; Abe, T; Takeuchi, Y; Ochiai, H; Moriyoshi, M; Kawata, K

    1992-07-01

    Two experiments were carried out to examine therapeutic effect of a gonadotropin-releasing hormone analog, buserelin, on ovarian follicular cysts in dairy cows. Follicular cysts were diagnosed by palpation per rectum as well as by milk progesterone assay. Luteinization of the follicular cysts following treatment was judged by an increase in milk progesterone. In Experiment 1, 35 cows were diagnosed to have follicular cysts on the basis of palpations and low milk progesterone concentrations 1 week before treatment. Another 19 cows which were clinically diagnosed with follicular cysts but showed high milk progesterone levels before treatment were excluded. Sixty-two percent (11/18) of cows with follicular cysts treated with 20 microg of buserelin and 82% (14/17) of cows treated with 10,000 IU of human chorionic gonadotropin (hCG) showed luteinization of follicular cysts within 4 to 5 days after the treatments. The percentage of cows conceiving within 100 days after treatment and the average interval in days between treatment and conception were 44% and 42+/-18 (SD) days for the buserelin-treated cows and 47% and 42+/-18 days for the hCG-treated cows. In Experiment 2, the effects of treatment doses (6, 10, 20 and 30 microg of buserelin and 10,000 IU of hCG) on follicular cysts were compared using 103 cows. An additional 23 cows which were clinically diagnosed as having follicular cysts and which were given treatment showed a high milk progesterone concentration on the day of treatment and were therefore excluded. Fifty to 64% of the cows responded with luteinization of follicular cysts after treatment. There was no significant difference in response among cows given either the different dosages of buserelin or the hCG. However, the percentage of the total number of cows that conceived after a single or a repeated treatment with 6 microg buserelin was lower than that of cows after a single or a repeated treatment with 10 microg buserelin (Povarian follicular cysts in

  3. Pharmacokinetics and Bioavailability of the GnRH Analogs in the Form of Solution and Zn2+-Suspension After Single Subcutaneous Injection in Female Rats.

    Science.gov (United States)

    Suszka-Świtek, Aleksandra; Ryszka, Florian; Dolińska, Barbara; Dec, Renata; Danch, Alojzy; Filipczyk, Łukasz; Wiaderkiewicz, Ryszard

    2017-04-01

    Although many synthetic gonadoliberin analogs have been developed, only a few of them, including buserelin, were introduced into clinical practice. Dalarelin, which differs from buserelin by just one aminoacid in the position 6 (D-Ala), is not widely used so far. Gonadotropin-releasing hormone (GnRH) analogs are used to treat many different illnesses and are available in different forms like solution for injection, nasal spray, microspheres, etc. Unfortunately, none of the above drug formulations can release the hormones for 24 h. We assumed that classical suspension could solve this problem. Two sets of experiments were performed. In the first one, buserelin and dalarelin were injected into mature female rats in two forms: suspension, in which the analogs are bounded by Zn2+ ions and solution. The pharmacokinetic parameters and bioavailability of the analogs were calculated, based on their concentration in the plasma measured by high-performance liquid chromatography method (HPLC). In the second experiment, the hormones in two different forms were injected into superovulated immature female rats and then the concentration of Luteinizing hormone (LH), Follicle-stimulating hormone (FSH) and 17β-estradiol in the serum was measured by radioimmunological method. The Extent of Biological Availability (EBA), calculated on the base of AUC0-∞, showed that in the form of solution buserelin and dalarelin display, respectively, only 13 and 8 % of biological availability of their suspension counterparts. Comparing both analogs, the EBA of dalarelin was half (53 %) that of buserelin delivered in the form of solution and 83 % when they were delivered in the form of suspension. The injection of buserelin or dalarelin, in the form of solution or suspension, into superovulated female rats increased LH, FSH and estradiol concentration in the serum. However, after injection of the analogs in the form of suspension, the high concentration of LH and FSH in the serum persisted

  4. A randomized double blind clinical trial of two GnRH analogs for the treatment of cystic ovaries in dairy cows.

    Science.gov (United States)

    Dinsmore, R P; White, M E; Guard, C L; Jasko, D J; Perdrizet, J A; Powers, P M; Smith, M C

    1987-07-01

    A randomized double blind clinical trial was conducted to compare the efficacy of the gonadotrophin-releasing hormone, buserelin, to that of the hormone gonadorelin for the treatment of bovine ovarian cysts. Two hundred and sixty five cows with a clinical diagnosis of follicular cysts were included in the study. At 30 days post treatment 85% of the gonadorelin and 89% of the buserelin treatment groups no longer had a palpable ovarian cyst. No significant differences were found between treatment groups in the number of cows bred by 90 days post treatment, conception rate by 90 days post treatment, services per conception, milk progesterone at 30 days post treatment, days post treatment to first heat, and days post treatment to conception.

  5. Binding properties of solubilized gonadotropin-releasing hormone receptor: role of carboxylic groups

    Energy Technology Data Exchange (ETDEWEB)

    Hazum, E.

    1987-11-03

    The interaction of /sup 125/I-buserelin, a superactive agonist of gonadotropin-releasing hormone (GnRH), with solubilized GnRH receptor was studied. The highest specific binding of /sup 125/I-buserelin to solubilized GnRH receptor is evident at 4/sup 0/C, and equilibrium is reached after 2 h of incubation. The soluble receptor retained 100% of the original binding activity when kept at 4 or 22/sup 0/C for 60 min. Mono- and divalent cations inhibited, in a concentration-dependent manner, the binding of /sup 125/I-buserelin to solubilized GnRH receptor. Monovalent cations require higher concentrations than divalent cations to inhibit the binding. Since the order of potency with the divalent cations was identical with that of their association constants to dicarboxylic compounds, it is suggested that there are at least two carboxylic groups of the receptor that participate in the binding of the hormone. The carboxyl groups of sialic acid residues are not absolutely required for GnRH binding since the binding of /sup 125/I-buserelin to solubilized GnRH receptor was only slightly affected by pretreatment with neuraminidase and wheat germ agglutinin. The finding that polylysines stimulate luteinizing hormone (LH) release from pituitary cell cultures with the same efficacy as GnRH suggest that simple charge interactions can induce LH release. According to these results, the authors propose that the driving force for the formation of the hormone-receptor complex is an ionic interaction between the positively charged amino acid arginine in position 8 and the carboxyl groups in the binding site.

  6. A comparative therapeutic management of anoestrus in buffaloes using insulin and GnRH

    Directory of Open Access Journals (Sweden)

    R. D. Purkayastha

    2015-06-01

    Full Text Available Aim: Anoestrus is one of the most common functional disorders of the reproductive cycle in buffaloes. In spite of technical advancement, there is no single cure for the management of anoestrus. Therefore, the aim of this study was to find out the efficacy of gonadotropic releasing hormone (GnRH and metabolic hormone for the management of true anoestrus in buffaloes. Materials and Methods: The experimental animals were selected on the basis of history, gyneco-clinical examinations and progesterone estimation. Deworming was done with Fenbendazole and thereafter mineral mixture was given @ 50 g per animal per day for 10 days in all the selected buffaloes before the start of treatment. The selected buffaloes were randomly divided into four groups (n=25. In Group I, buffaloes were administered 20 μg of buserelin intramuscularly. Buffaloes of Group II were administered long-acting insulin @ 0.25 IU/Kg body weight subcutaneously for 5 consecutive days. In Group III, buffaloes were treated with a combination of insulin and buserelin in the above-mentioned doses whereas buffaloes of Group IV were kept as untreated control. Results: The higher oestrus induction (64% vs. 28% was found in Group III and differed significantly (p<0.05 as compared to control group. The conception rate (69.23% vs. 66.66% was also found higher in Group III but did not differ significantly among the treated groups. The mean time taken for the onset of oestrus was recorded significantly shorter in insulin (8.80±0.69 and GnRH (7.60±0.92 days alone and as compared to other (Group III, 14.43±0.83 and Group IV, 20.57±1.69 days groups. Conclusion: The results of this study indicated better fertility response using Insulin plus Buserelin in true anoestrus buffaloes under field conditions.

  7. [Dairy cattle pregnancy rate in fixed time artificial insemination program with and without ultrasonic gynecologic screening.

    Directory of Open Access Journals (Sweden)

    Gustavo Fernandes Grillo

    2016-06-01

    Full Text Available To evaluate the pregnancy rate and the importance of ultrasound gynecological screening (US performed prior to fixed time artificial insemination programs (TAI, 120 Girolando cows, over two breeding seasons (2013 and 2014, were divided into two groups: (C / T; n = 58 and without (S / T; n = 62 gynecological screening by ultrasound, using three protocols, and the same for the groups with and without screening. Protocol I - “OvSynch” (OV in which received 0.025 mg of buserelin acetate in D0; 0.15 mg d-cloprostenol on D7; 0.025 mg buserelin acetate D9; It is inseminated at fixed time in D10. Protocol II - “OvSynch” + progesterone (OP4 and III Protocol - “OvSynch” + LH + P4 (OP4LH. Protocols II and III followed the same dosages of “OvSynch” associated with the introduction of intravaginal device containing 1g first use of progesterone in D0 and D7 in withdrawal. In Protocol III, LH replaced buserelin acetate in ovulation induction (D9; 25mg. Gestation diagnosis was made by US 45 days after TAI, and the animals not pregnant were reinseminated as presented heat. Parameters pregnancy rate at TAI (TP, total pregnancy rate (TPT = TAI + Return heat were analyzed by Chi-square or Fisher’s exact with 5% significance level. The use of progesterone favored the pregnancy rate of cyclic and acyclic animals, this has not occurred with LH job as ovulation inductor, providing no increase in pregnancy rates and overall pregnancy rate of dairy cows referred to the rated protocol. The gynecological screening by ultrasonography allowed evaluating the cyclicity of the studied females, indicating that its previous execution to the TAI, can provide good results with the use of better efficiency protocols for TAI programs.

  8. Intrauterine fertilization capsules--a clinical trial

    DEFF Research Database (Denmark)

    Lenz, S; Lindenberg, S; Sundberg, K

    1991-01-01

    Treatment of 26 women with tubal infertility was attempted using intrauterine capsules loaded with oocytes and spermatozoa. The stimulation protocol was as used for in vitro fertilization and embryo transfer and consisted of short-term use of Buserelin, human menopausal gonadotropin, and human...... and piston from an intrauterine device. Six complete capsules and parts of two other capsules were expelled. None of the women became pregnant, compared with a pregnancy rate of 21% per aspiration following in vitro fertilization and embryo transfer during the same period....

  9. Reproductive responses of dairy cows with ovarian cysts to simultaneous human chorionic gonadotropin or gonadotropin-releasing hormone and cloprostenol compared to gonadotropin-releasing hormone alone treatment

    Directory of Open Access Journals (Sweden)

    T. Taktaz

    2015-05-01

    Full Text Available Aim: Bovine ovarian cysts are a common cause of economic loss in modern dairy herds. The objective of the present study was to evaluate the reproductive responses to three protocols using hCG, GnRH and cloprostenol when the definite diagnosis of the type of ovarian cyst is/is not possible in dairy cows. Materials and Methods: A total of 144 lactating dairy cows with ovarian cysts were divided into three groups. At diagnosis (Day 0, cows in Group 1 (the conventional method, n=47 were injected with 0.02 mg of a GnRH analogue i.m. (Buserelin; cows in Group 2 (n=47 were intramuscularly treated with 0.02 mg Buserelin plus 500 μg cloprostenol; and cows in Group 3 (n=50 were intramuscularly treated with 1500 IU hCG plus 500 μg cloprostenol. All cows received 500 μg cloprostenol intramuscularly on Day 10. Results: No statistically significant differences were found in the recovery time, interval to conception, conception rate at first AI, and pregnancy rates by Days 70 and 100 after treatment among the three groups. Conclusions: Simultaneous treatment of ovarian cysts with hCG or GnRH and cloprostenol appeared to have no advantage over the conventional method, GnRH alone, in dairy cows. Furthermore, hCG and GnRH have an equal therapeutic effect in cows with ovarian cysts.

  10. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction

    DEFF Research Database (Denmark)

    Andersen, C Yding; Al Humaidan, Peter Samir Heskjær; Ejdrup, H Bredkjaer

    2006-01-01

    BACKGROUND: A recent prospective randomized study from our group compared GnRH agonist (0.5 mg buserelin) and hCG (10,000 IU) for triggering of ovulation following a flexible antagonist protocol. The agonist group showed a poor reproductive outcome despite luteal phase support with progesterone......-ovulatory follicular maturation resulting in oocytes with a compromised developmental competence. METHODS: Hormone concentrations were measured in two individual follicular fluid samples from each of 32 women receiving buserelin and 37 receiving hCG, thus representing a subset of the follicles retrieved. RESULTS......: Follicular fluid levels of LH in the agonist group as compared with the hCG group was 11.1 +/- 0.5 versus 3.6 +/- 0.3 IU/l (mean +/- SEM; P hCG, not determined versus 139+/-8 IU/l; E(2), 1.9 +/- 0.2 versus 1.8 +/- 0.2 micromol/l (P > 0...

  11. Estrus synchronization and Fixed Time Artificial Insemination (FTAI in dairy buffaloes during seasonal anestrus

    Directory of Open Access Journals (Sweden)

    Luciana Ferri Frares

    2013-08-01

    Full Text Available The aim of this work was to study estrus synchronization and fixed time artificial insemination (FTAI in dairy buffaloes during season anestrus. One hundred thirty-nine dairy buffaloes in seasonal anestrus were divided in two groups as G1(n=66 and G2(n=73. The protocols for both the groups were the same until day (D14:D0 administration of 2.0 mg estradiol benzoate and implantation of progesterone device (P4 for 14 days; D14 removal of P4 plus 150 mg of cloprostenol and 400 IU of equine chorionic gonadotropin. On D16, G1 received 10 mg of buserelin and G2 100 mg deslorelin acetate. On D17, both the groups were submitted to FTAI. Ultrasonographic examinations of ovaries were performed on D0, D14, D16 and D17. Results showed that pregnancy rates in G1 and G2 were 20 and 41% (p0.05. Thirty-five percent of the animals in G1 and 54.1% in G2 showed a diameter DF greater than 8.0 mm on D16 (p>0.05. Thus, it could be concluded that the protocols synchronized the estrus, leading the concentration of the parturitions in the period of low milk production. Deslorelin was more efficient than buserelin due the higher percentage of DF ovulation and higher pregnancy rates.

  12. [Gonadotropin release and course of diseases after administration of a GnRH-analog in cattle with follicular-thecal cysts].

    Science.gov (United States)

    Grunert, E; Völker, R; Schams, D; Schallenberger, E

    1992-04-01

    Twenty-five heifers and cows with follicular cysts (high level of total oestrogens, low level of progesterone in plasma) were treated with 20 or 50 micrograms buserelin i.m. 5-84 weeks after parturition. Two hours after medication an increased LH release was observed in all animals. In contrast to LH, FSH concentration was not increased in all cows. Twelve days after treatment a high progesterone concentration in plasma could be determined in 17 of 25 treated animals. Twenty cows showed oestrous symptoms 23.5 +/- 9.6 days after medication. The oestrous cycle was prolonged in 10 cows. Nineteen cows were inseminated and 14 cows became pregnant after 1-4 (phi 1.7 +/- 0.9) inseminations (73.6% of all inseminated cows and 56% of all treated cows). The differences in conception rate and in services per conception after treatment with 20 or 50 micrograms buserelin in favour of the higher dosage cannot be attributed to the medication.

  13. Erythropoietin may reduce the risk of germ cell loss in boys with cryptorchidism

    DEFF Research Database (Denmark)

    Cortes, Dina; Visfeldt, J; Thorup, J M

    2001-01-01

    In boys with cryptorchidism older than 2 years a testicular biopsy at time of orchiopexy shows lack of germ cells in 10-40% of the cases. The number of spermatogonia per tubule is prognostic for subsequent fertility potential. A biopsy without germ cells is associated with 33-100% risk...... of infertility. In order to increase the number of germ cells, and thereby the fertility potential, additional hormonal therapy has been attempted before surgery. In a study, small doses of the gonadotropin-releasing hormone analogue buserelin before orchiopexy caused higher values. Others have found...... that hormonal treatment with human chorionic gonadotropin or gonadotropin releasing hormone analogue may harm the germ cells in cryptorchidism. The aim of the study is to demonstrate that additional hormonal therapy with erythropoietin has a positive effect on the number of germ cells....

  14. Premenstrual Exacerbation of Life-Threatening Asthma: Effect of Gonadotrophin Releasing Hormone Analogue Therapy

    Directory of Open Access Journals (Sweden)

    Alun L Edwards

    1996-01-01

    Full Text Available Variability in the severity of asthma during various phases of the menstrual cycle has been frequently suspected. However, the hormonal changes that might affect mediators of bronchospasm have yet to be elucidated. The case of a 41-year-old woman suffering from longstanding asthma with life-threatening exacerbations is reported. The patient was treated with buserelin, a gonadotropin releasing hormone (GnRH analogue, which created a temporary chemical menopause and thus permitted diagnosis of a premenstrual exacerbation of asthma and offered insight into potential therapy. GnRH analogues may therefore be of value in assessing women with severe asthma suspected to vary with the menstrual cycle. The addition of estrogens and progestins at the same time as treatment with GnRH analogue may be of value in determining the role of these hormones in the pathogenesis of menstrually related exacerbations of asthma.

  15. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty

    DEFF Research Database (Denmark)

    Juul, A; Scheike, Thomas Harder; Nielsen, C T

    1995-01-01

    Central precocious puberty (CPP) is characterized by early activation of the pituitary-gonadal axis, which leads to increased growth velocity and development of secondary sexual characteristics. It is generally believed that gonadal sex steroids stimulate pulsatile GH secretion, which, in turn......, stimulates insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) production. However, little is known about GH, IGF-I, and IGFBP-3 serum levels in children with precocious puberty. Treatment of CPP by GnRH agonists has become the treatment of choice. However, the effect of long term...... treatment with GnRH in combination with an antiandrogen (cyproterone acetate) to block the possible effect of adrenal androgens has not previously been evaluated. We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination...

  16. Erythropoietin may reduce the risk of germ cell loss in boys with cryptorchidism

    DEFF Research Database (Denmark)

    Cortes, D; Visfeldt, J; Thorup, J M

    2001-01-01

    of infertility. In order to increase the number of germ cells, and thereby the fertility potential, additional hormonal therapy has been attempted before surgery. In a study, small doses of the gonadotropin-releasing hormone analogue buserelin before orchiopexy caused higher values. Others have found......: Erythropoietin (Eprex) 100 IU/kg were administered subcutaneously weekly for 3 months prior to surgery in two cryptorchid boys, 6 months old and 1 year 9 months old, respectively, with renal function impairment. RESULTS: The number of spermatogonia per tubular cross-section in testicular biopsies was unusually...... that hormonal treatment with human chorionic gonadotropin or gonadotropin releasing hormone analogue may harm the germ cells in cryptorchidism. The aim of the study is to demonstrate that additional hormonal therapy with erythropoietin has a positive effect on the number of germ cells. MATERIALS AND METHODS...

  17. β-Nerve growth factor is a major component of alpaca seminal plasma and induces ovulation in female alpacas.

    Science.gov (United States)

    Kershaw-Young, C M; Druart, X; Vaughan, J; Maxwell, W M C

    2012-01-01

    Ovulation in camelids is induced by an unidentified protein in the seminal plasma of the male termed 'ovulation-inducing factor'. This protein has been reported to be a 14-kDa protein under reducing conditions, which, when purified from seminal plasma, induces ovulation in llamas. The identification of this protein and investigation of its potential to induce ovulation in camelids may aid the development of protocols for the induction of ovulation. In the present study, alpaca seminal plasma proteins were separated using one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the most abundant protein of 14 kDa was identified as β-nerve growth factor (β-NGF) by liquid chromatography mass spectrometry. Female alpacas (n = 5 per group) were given intramuscular injections of: (1) 1 mL of 0.9% saline; (2) 4 µg buserelin, a gonadotrophin-releasing hormone agonist; (3) 2 mL alpaca seminal plasma; or (4) 1mg human β-NGF. Ovulation was detected by transrectal ultrasonography 8 days after treatment and confirmed by plasma progesterone concentrations. Ovulation occurred in 0%, 80%, 80% and 80% of animals treated with saline, buserelin, seminal plasma and β-NGF, respectively. Treatment type did not affect the diameter of the corpus luteum, but plasma progesterone concentrations were lower in saline-treated animals than in the other treatment groups owing to the lack of a corpus luteum. The present study is the first to identify the ovulation-inducing factor protein in alpacas. β-NGF successfully induces ovulation in alpacas and this finding may lead to new methods for the induction of ovulation in camelids.

  18. Intravaginal instillation of gonadotropin-releasing hormone analogues with an absorption enhancer induced a surge of luteinizing hormone in lactating dairy cows.

    Science.gov (United States)

    Wijma, R; Stangaferro, M L; Masello, M; Elmetwally, M A; Granados, G E; Amovilli, F; Giordano, J O

    2017-09-01

    Our objectives were to evaluate circulating LH concentrations after intravaginal (IVG) instillation of GnRH analogs in lactating dairy cows. In 2 experiments, lactating Holstein cows (experiment 1: n = 32; experiment 2: n = 47) received the experimental treatments 48 h after the first of 2 PGF2α treatments given 12 h apart and 7 d after a modified Ovsynch protocol (GnRH at -7 d, PGF2α at -24 h, PGF2α at -56 h, GnRH at 0 h). In experiment 1, cows were stratified by parity and randomly allocated to receive the following treatments: 2 mL of saline IVG (SAL, n = 6), 100 µg of gonadorelin (Gon) i.m. (G100-IM, n = 5), and 100 (G100, n = 7), 500 (G500, n = 8), or 1,000 µg of Gon IVG (G1000, n = 7). In experiment 2, treatments were SAL (n = 8), G100-IM (n = 8), G1000 (n = 7), 1,000 µg of Gon plus 10% citric acid (CA) IVG (G1000CA, n = 8), 80 µg of buserelin IVG (B80, n = 8), and 80 µg of buserelin plus 10% CA IVG (B80CA, n = 8). In both experiments, blood was collected every 15 min from -15 min to 4 h, and every 30 min from 4 to 6 h after treatment. Data for area under the curve (AUC), mean LH concentrations, and time to maximum LH concentration were analyzed by ANOVA with (mean LH only) or without repeated measures using PROC MIXED of SAS (version 9.4, SAS Institute Inc., Cary, NC). The proportion of cows with a surge of LH was evaluated with Fisher's exact test using PROC FREQ of SAS. In both experiments, LH concentrations were affected by treatment, time, and the treatment by time interaction. In experiment 1, the AUC for LH and maximum LH concentration were greatest for the G100-IM treatment and were greater for the G1000 than for the SAL and G500 treatments. The proportion of cows with an observed surge of LH was 100 and 0% for cows that received Gon i.m. and IVG, respectively. In experiment 2, the AUC and maximum LH concentrations were greater for the G100-IM, G1000CA, and B80CA treatments than for the other IVG treatments. The proportion of cows with a surge

  19. High ovarian response in Yoruba African women during ovulation induction for assisted conception.

    Science.gov (United States)

    Wada, I; Matson, P L; Macnamee, M C; Brinsden, P R; Lieberman, B A

    1994-06-01

    Fertile Yoruba women from western Nigeria have a much higher incidence of naturally conceived multizygotic twin and triplet pregnancies than Caucasians. The objective of the present study was to determine whether there are differences between infertile Yoruba and Caucasian women in terms of ovarian response in stimulate cycles for assisted conception. A total of 11 Yoruba women were scheduled for 14 in-vitro fertilization (IVF) and one gamete intra-Fallopian transfer (GIFT) cycles from 1990 to 1992. The Caucasian group consisted of 209 women scheduled for 213 IVF and 22 GIFT cycles during the same period. Buserelin, 500 micrograms subcutaneously daily, was started in the mid-luteal phase to achieve pituitary desensitization. Ovarian stimulation was with variable amounts of menopausal gonadotrophins. Human chorionic gonadotrophin (HCG) was given to trigger the ovulatory process. The Yoruba and Caucasian groups were similar in age and body weight, but significantly more Yorubas (45 versus 11%; P 14 mm in diameter (15.5 versus 9.5; P Yoruba group. The ovarian hyperstimulation syndrome (OHSS) was also more prevalent in the Yoruba group (20 versus 5%; P Yoruba than Caucasian women, associated with a higher prevalence of PCOS. The risk of developing symptomatic OHSS is higher in Yoruba women.

  20. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation

    DEFF Research Database (Denmark)

    Humaidan, Peter; Polyzos, N P; Alsbjerg, B

    2013-01-01

    STUDY QUESTION: Does a GnRH agonist (GnRHa) trigger followed by a bolus of 1.500 IU hCG in a group of patients at risk of ovarian hyperstimulation syndrome (OHSS) reduce the OHSS incidence compared with hCG trigger? SUMMARY ANSWER: A GnRHa trigger followed by early luteal hCG support with one bolus...... of 1.500 IU hCG appears to reduce OHSS in patients at risk of OHSS; however, in a low-risk group a second bolus of 1.500 IU hCG induced two cases of late onset OHSS. WHAT IS KNOWN ALREADY: A GnRHa trigger is an alternative to hCG in GnRH antagonist co-treated cycles. STUDY DESIGN, SIZE, DURATION: Two......RHa) s.c. followed by a single bolus of 1.500 IU hCG s.c. after the oocyte retrieval-or: Group B (n = 58): 5.000 IU hCG. Similarly, women at low risk of OHSS were allocated (RCT 2) to receive either: Group C (n = 125), a bolus of 0.5 mg buserelin s.c., followed by a bolus of 1.500 IU hCG s.c. after...

  1. DMRTC2, PAX7, BRACHYURY/T and TERT Are Implicated in Male Germ Cell Development Following Curative Hormone Treatment for Cryptorchidism-Induced Infertility.

    Science.gov (United States)

    Gegenschatz-Schmid, Katharina; Verkauskas, Gilvydas; Demougin, Philippe; Bilius, Vytautas; Dasevicius, Darius; Stadler, Michael B; Hadziselimovic, Faruk

    2017-10-11

    Defective mini-puberty results in insufficient testosterone secretion that impairs the differentiation of gonocytes into dark-type (Ad) spermatogonia. The differentiation of gonocytes into Ad spermatogonia can be induced by administration of the gonadotropin-releasing hormone agonist, GnRHa (Buserelin, INN)). Nothing is known about the mechanism that underlies successful GnRHa treatment in the germ cells. Using RNA-sequencing of testicular biopsies, we recently examined RNA profiles of testes with and without GnRHa treatment. Here, we focused on the expression patterns of known gene markers for gonocytes and spermatogonia, and found that DMRTC2, PAX7, BRACHYURY/T, and TERT were associated with defective mini-puberty and were responsive to GnRHa. These results indicate novel testosterone-dependent genes and provide valuable insight into the transcriptional response to both defective mini-puberty and curative GnRHa treatment, which prevents infertility in man with one or both undescended (cryptorchid) testes.

  2. Measurement of testosterone and cortisol metabolites and luteinising hormone in captive southern hairy-nosed wombat (Lasiorhinus latifrons) urine.

    Science.gov (United States)

    Du, Z; Keeley, T; Janssen, T; Nicolson, V; Johnston, S D

    2017-09-01

    This study reports the validation and use of enzyme immunoassays (EIA) to measure changes in plasma and urinary luteinizing hormone, testosterone metabolites (UTM) and cortisol metabolites (UCM) in captive southern hairy-nosed wombats (Lasiorhinus latifrons). GnRH agonist and ACTH agonist challenges were conducted to validate urinary testosterone (male wombat only) and cortisol (male and female wombats) EIAs. Following intra-muscular injection of 8-12μg buserelin (n=4 males), there was a significant increase in both plasma (Ptestosterone concentrations (P<0.001) 60min and 21h after administration, respectively. Plasma LH levels were elevated (p<0.05) at 20min but there was no significant increase found in urinary LH concentrations after injection. Intra-muscular injection of Synacthen® Depot (250μg) (n=3 males, 3 females) resulted in a significant increase (p<0.05) in plasma cortisol secretion 15min and in urinary cortisol concentrations 3h post injection, respectively. Sex-related differences in cortisol secretion were also reported in this study. These findings indicate that (1) urinary LH might not be an appropriate index for describing the reproductive status in captive male L. latifrons, and (2) the UTM and UCM assays appear to be suitable for the assessment of the testicular steroidogenic capacity and the adrenocortical activity in captive southern hairy-nosed wombats, respectively. Copyright © 2017 Elsevier Inc. All rights reserved.

  3. Evaluation of Pre and Post Artificial Insemination effect of GnRH Hormone on conception of repeat breeder Deoni Cows

    Directory of Open Access Journals (Sweden)

    S.D. Awati

    2010-10-01

    Full Text Available Twenty four Deoni repeat breeder cows were randomly allocated into 4 groups of six each. The animals of groups I, II and III were injected with 250 µg of buserelin acetate (Receptal® on two occasions i.e. once on day of estrus and second dose on days 10 or 12 or14 respectively in I, II and III groups following breeding, while the animals of group IV served as control. Among the physical characters of estrual cervico-vaginal mucous, typical arborization pattern (80.95 % in pregnant vs. 55.56 % in non-pregnant cows and marginally high spinnbarkeit readings (24.67+2.7cms in pregnant and 22.21+1.32 cms in non-pregnant cows favored better fertility, although the differences between the groups were statistically insignificant. However, the pH of estrual cervico-vaginal mucous did not indicate any effect on fertility and it ranged between 8.00 to 9.00. The cows of treatment groups I, II and III registered a considerably higher conception rate of 83.33 percent each, while in control group cows had only 33.33 percent. To conclude GnRH therapy irrespective of days of administration resulted in an overall enhancement in conception rate of 83.33 as against 33.33 percent in control groups of cows. [Vet. World 2010; 3(5.000: 209-211

  4. Production, Preservation, and Transfer of South American Camelid Embryos

    Directory of Open Access Journals (Sweden)

    Virginia L. Trasorras

    2017-11-01

    Full Text Available The current review summarizes progress in the field of in vitro and in vivo production of South American Camelid embryos. Both methods require ovarian superstimulation (with FSH and eCG to obtain multiple ovulations (in vivo embryo production or to induce follicle growth for oocyte collection (in vitro embryo production. Moreover, superstimulation entails prior administration of hormones that inhibit follicular growth (progesterone, progestagens, and estrogens. Cumulus-oocyte complexes obtained must mature in vivo (buserelin administration or in vitro to then be subjected to in vitro fertilization or intracytoplasmic sperm injection. All these techniques also require morphologically normal, motile spermatozoa to achieve fertilization. Methods used to decrease semen viscosity and to select the best spermatozoa (Percoll®; Androcoll-ETM are described. Additionally, nuclear transfer or cloning has been applied in llamas. Up to now, embryo deep-freezing and vitrification have progressed slowly but are at the height of development. Embryos that are obtained by any of these techniques, either in vivo or in vitro, need to be transferred to synchronized recipient females. The best results are achieved after transfer to the left uterine horn with an ipsilateral ovulation. No live offspring have been obtained after the transfer of cryopreserved embryos. Applying reproductive biotechnologies, such as those described, will permit the expansion of genetically selected animals in the population and also that of wild camelid species, vicunas, and guanacos, whose embryos could then be transferred to the uterus of domestic species.

  5. [Direct and indirect costs of luteinising hormone-releasing hormone analogues in the treatment of locally advanced or metastatic prostate cancer in Italy].

    Science.gov (United States)

    Fadda, Valeria; Maratea, Dario

    2015-12-01

    When analyzing the use of luteinizing hormone-releasing hormone (LHRH) analogues for different clinical indications, current available evidence does not support a presumed drug class effect among the various LHRH in the treatment of prostate cancer. The following search key words were entered in the PubMed database and the NICE and FDA websites: “LHRH agonist AND prostatic cancer”, “androgen deprivation therapy”, “androgen suppression”, “buserelin”, “leuprorelin”, “goserelin”,“triptorelin”, “degarelix”. The direct costs included the following items: follow-up visits, diagnostic exams (e.g. prostate-specific antigen PSA) and drug costs. The indirect costs included working days lost by the patient. With intermittent therapy as a reference, leuprorelin injectable solution of 22,25 mg was associated with the lowest cost and degarelix with the highest cost. However, given the mandatory presence of a nurse for drug injection, the buserelin depot formulation was associated with the lowest cost. If the costs for hospital visits were added to drug costs, differences between the various therapeutic strategies were less remarkable. Our study showed how various factors (e.g. route of administration, frequency of administration, presence of a nurse for drug reconstitution and injection) should be taken into account by decision makers in addition to the price of drugs.

  6. Buffer salt effects in off-line coupling of capillary electrophoresis and mass spectrometry.

    Science.gov (United States)

    Marák, Jozef; Stanová, Andrea

    2014-05-01

    In this work, the impact of buffer salts/matrix effects on the signal in direct injection MS with an electrospray interface (DI-ESI-MS) following pITP fractionation of the sample was studied. A range of buffers frequently used in CE analyses (pH 3-10) was prepared containing 10, 50, and 90% v/v of ACN, respectively. The sets of calibration solutions of cetirizine (an antihistaminic drug with an amphiprotic character) within a 0.05-2.0 mg/L concentration range were prepared in different buffers. The greatest enhancements in the MS signal (in terms of change in the slope of the calibration line) were obtained for the beta-alanine buffer (pH 3.5) in positive ionization and for the borate buffer (pH 9.2) in negative ionization, respectively. The procedure was successfully applied to the analysis of buserelin (a peptidic drug). The slope of the calibration line for solutions containing the beta-alanine buffer with 50% of ACN was 4 times higher than for water or urine, respectively. This study clearly demonstrates that the buffer salt/matrix effects in an offline combination of pITP and DI-ESI-MS can also play a positive role, as they can enhance the signal in MS. A similar influence of the above effects can also be presumed in the CE techniques combined on-line with ESI-MS.

  7. Woman with surgical reconstruction of anal atresia who realized pregnancy with in vitro fertilisation

    Directory of Open Access Journals (Sweden)

    Garalejić Eliana

    2010-01-01

    Full Text Available Introduction. Anal atresia is a congenital anomaly, very life threatening and urgent. Surgical treatment of this anomaly consists of colostomy first, and then of anal reconstruction. Case report. We presented a 31-year old female with the surgery treatment of anal atresia in the early childhood. In the reproductive period, due to tubal infertily, the patient was included in the program of in vitro fertilization (IVF, in the Clinic for Gynecology and Obstetrics 'Narodni front', Belgrade. Within this program a long protocol of ovarian stimulation was performed. Ultrasonographic and color Doppler monitoring of the patient was applied by the use of an ultrasonographic apparatus type Siemens Acuson X 150, while any hormonal examinations were performed by an Architect Abbott unit. During the IVF program, the growth of follicules was controlled by the use of ultrasonography, microcirculation of the ovaries and the uterus was marked by a power-pulsating color Doppler, and hormonal examination was performed starting from the day of stimulation up to the day of injecting Pregnyl®. The patient was administered Suprefact® (buserelin sc from the 21st day of the menstrual cycle, as well as from the 3rd day of the cycle, for totally 11 days. The patient was given 29 ampoules of Gonal F® (recombinant human FSH 75 IJ im and 15 ampoules of Menopur® (menotrophin im. Due to a modified pelvic anatomy, the left ovary aspiration was disabled, while the right ovary aspired seven oocytes successfully. Three embryos were inserted in the uterus. The delivery was performed by cesarean section. Conclusion. In the reported patient with a modified pelvic anatomy due to four corrective surgeries of anal atresia, and tubal infertility in the reproductive period, the method of choice for the realization of pregnancy was the IVF procedure. The realized pregnancy and the delivery could be considered highly successful in regard to possible risks.

  8. Retrospective analysis of the efficacy of different hormone treatments of cystic ovarian disease in cattle.

    Science.gov (United States)

    Nanda, A S; Ward, W R; Williams, P C; Dobson, H

    1988-02-13

    Cystic ovarian disease in cows was treated either with a single intramuscular injection of 500 micrograms cloprostenol, a prostaglandin F2 alpha analogue, in 77 cases of luteal cysts or with 500 micrograms gonadorelin or 20 micrograms buserelin, gonadotrophin releasing hormone or its analogue (GnRH), in 116 cases of follicular cysts. Recovery was defined as the absence of cysts and the formation of a corpus luteum either with or without observed oestrus within 10 days after treatment with cloprostenol and 15 days after treatment with GnRH. Recovery occurred in 65 per cent and 52.6 per cent of cases, respectively, in average times of 4.9 and 19 days. Fifteen days after treatment with GnRH, 20 cows with luteinised cysts were treated with cloprostenol and 15 recovered in a mean of 20.4 days, while 10 which still had follicular cysts, were given GnRH and one recovered 31 days after the beginning of treatment. Another 27 cows, in which cysts became luteinised, were treated with cloprostenol seven days after treatment with GnRH to give quicker (average 11.5 days) but poor (48 per cent) recovery and with a higher rate (33 per cent) of recurrence of cysts. A progesterone releasing intrauterine device was used in 25 cases of cystic ovarian disease, some of which had been previously treated. Sixty-eight per cent recovered in an average of 15 days. The proportions of cows becoming pregnant to one to three inseminations after the different methods of treatment were similar (77 to 94 per cent).(ABSTRACT TRUNCATED AT 250 WORDS)

  9. EFFECT OF GnRH AND PHOSPHORUS IN DELAYED PUBERTAL SURTI BUFFALO HEIFERS

    Directory of Open Access Journals (Sweden)

    H.B. Dhamsaniya

    2016-06-01

    Full Text Available The study was conducted on eighteen delayed pubertal Surti buffalo heifers, divided into three equal groups (6 in each to evaluate the efficacy of GnRH alone and in combination of phosphorus. The buffalo heifers in Group-I and Group-II were treated with Buserelin acetate (5 ml, IM. Buffalo heifers in Group-II also received additional injection of Toldimphos sodium (10 ml, IM at 3 day interval for 4 times, while buffalo heifers in Group-III served as control. The percentage of induced estrus was highest (83.33% in each treated groups as compared to control group (50%. The mean estrus induction intervals were significantly (P<0.05 shorter in Group-I (20.20 ± 2.18 days and Group-II (18.80 ± 2.32 days as compared to control group (30.24 ± 0.81 days. The conception rate at induced estrus was highest in Group-II (50% followed by Group-I (33.33%. The plasma progesterone levels being significantly lowest on the day of estrus (less than 0.5 ng/ml as compared to pre-treatment days in all groups. The mean total protein and triglycerides levels were differed significantly between the groups on the day of estrus and being significantly higher in Group-II as compared to Group-I and III on that day. A significantly higher level of cholesterol in both treatment groups as compared to the control group during different intervals and also being higher on the day of estrus as compared to pre-treatment days. The mean plasma glucose levels were differed nonsignificantly between and within the treatment and control groups. It is concluded that estrus can be successfully induced in delayed pubertal heifers with the use of GnRH alone and in combination with phosphorus.

  10. Comparison of In Vitro Fertilization Cycle Outcome between Patients with Polycystic Ovary Syndrome and Tubal Factor

    Directory of Open Access Journals (Sweden)

    Mahnaz Ashrafi

    2007-01-01

    Full Text Available Background: Infertility with an incidence of about 15% has been considered one of the majorburdens on the community and has even been a threat to the continuity of the family life. Oneof the most prevalent causes of women infertility is ovarian causes particularly PCOS. Theobjective of this study was to determine the outcome of IVF & ET in women with PCOS incomparison with tubal factor.Material and Methods: This historical cohort study was performed from 2000 to 2002, inRoyan Institute. Our cases consisted of 33 patients with PCOS (without any other causes ofinfertility who failed standard ovulation induction treatment with clomiphen citrate (≥6cycles and had undergone 33 cycles of IVF & ET. Control group consisted of 76 patientswith only tubal factor infertility. Our study was performed during the first cycle of IVF in twogroups, using long protocol with Buserelin (GnRHa and HMG. IVF and ET cyclecharacteristics were compared using student’s t-test, χ2 and Fisher's exact test.Results: The results of this research showed that a statistically significant difference existedin mean age and incidence of OHSS between the two groups. But there were no statisticallysignificant differences in duration of follicular phase, the duration of GnRHa use up to onsetof HMG, cyst number after using GnRHa, the percentage of cyst aspiration, HMG ampuleconsumption, retrieved oocyte, number of embryo per patient, embryo transfer per patient,cycle cancellation and pregnancy rate per embryo transfer in two groups.Conclusion: The result of this study showed that IVF/ET can be a successful treatmentin PCOS patients resistant to other usual treatments and that hormonal disturbance ofPCOs patients had no significant effect on IVF/ET outcome in comparison to patientswith tubal factor.

  11. A mixture of St. John's wort and sea buckthorn oils regresses endometriotic implants and affects the levels of inflammatory mediators in peritoneal fluid of the rat: A surgically induced endometriosis model.

    Science.gov (United States)

    İlhan, Mert; Süntar, İpek; Demirel, Mürşide Ayşe; Yeşilada, Erdem; Keleş, Hikmet; Küpeli Akkol, Esra

    2016-12-01

    Sea buckthorn (Hippophae rhamnoides L.) and St. John's wort (Hypericum perforatum L.) are used as an emmenagog and for the treatment of other gynecological disorders including uterus inflammation and endometriosis. The aim of the present study is to investigate the potential of a mixture of sea buckthorn and St. John's wort oils (HrHp oil) in the treatment of endometriosis. The activity was assessed in surgically induced endometriosis in rats. A 15-mm piece of endometrium was sutured into the abdominal wall. Twenty-eight days later, a second laparotomy was performed to calculate the endometrial foci areas and to score intra-abdominal adhesions. The rats were treated with either vehicle, HrHp oil formulation, or the reference (buserelin acetate). At the end of the experiment all rats were sacrificed and endometriotic foci areas and intra-abdominal adhesions were re-evaluated. The tissue sections were analyzed histopathologically. Peritoneal fluids of the experimental animals were collected in order to detect the levels of tumor necrosis factor-α, vascular endothelial growth factor, and interleukin-6, which might be involved in the etiology of endometriosis. In the HrHp oil-treated group, the volumes of endometriotic implants were found to be significantly decreased (from 50.8 mm 3 to 18.6 mm 3 , p<0.001) without any adhesion (0.0±0.0, p<0.001) when compared to the control group (3.1±0.9). The levels of tumor necrosis factor-α decreased from 7.02±1.33 pg/mL to 4.78±1.02 pg/mL (p<0.01); vascular endothelial growth factor from 17.39±8.52 pg/mL to 9.67±5.04 pg/mL (p<0.01); and interleukin-6 from 50.95±22.84 pg/mL to 29.11±7.45 pg/mL (p<0.01), respectively, after HrHp oil treatment. HrHp oil may be a promising alternative for the treatment of endometriosis. Copyright © 2016. Published by Elsevier B.V.

  12. Prenatal development of gonadotropin-releasing hormone receptors in the rat anterior pituitary

    Energy Technology Data Exchange (ETDEWEB)

    Jennes, L. (Wright State Univ. School of Medicine, Dayton, OH (USA))

    1990-02-01

    The development of pituitary GnRH receptors was studied in the rat with in vitro and in vivo autoradiography. GnRH receptors were first seen in pituitary primordia of 13-day-old fetuses. The binding was specific and saturable and was abolished in the presence of 10 microM synthetic GnRH. To examine whether GnRH was available to the fetus, amnionic fluid was collected on days E 12-18. RIA analyses showed that GnRH levels in the amnionic fluid were low on days 12 and 13 (0-20 pM/ml) and rose to 225 pM/ml on day E 16 before they declined to 110 pM/ml on fetal day E 18. The highest levels of GnRH in the amnionic fluid on day E 16 coincided with the first appearance of immunoreactive LH cells, as determined by immunohistochemistry. Intravenous injection of 500 microliters amnionic fluid into pentobarbital-anesthetized adult rats caused a transient 40-60% increase in circulating serum LH in the recipient animal. To show that GnRH from the amnionic fluid has access to the developing pituitary, the 125I-labeled GnRH agonist Buserelin was injected into the amnionic fluid of 13-, 14-, and 15-day-old fetuses in the presence or absence of 10 microM unlabeled GnRH. Autoradiographic analysis of the fetal tissue indicated that the labeled GnRH agonist bound to specific receptors in the primordial pituitaries. The results suggest that the pituitary gonadotropes are differentiated before day E 13 because the expression of GnRH receptors is already an indication of cell determination. Since GnRH is present in the amnionic fluid in a biologically active form and can reach the fetal pituitary, it is concluded that GnRH may be an important factor determining the onset LH synthesis, but not the differentiation, of primordial pituitary cells.

  13. Ultrasonographic-guided retrieval of cumulus oocyte complexes after super-stimulation in dromedary camel (Camelus dromedarius).

    Science.gov (United States)

    Wani, N A; Skidmore, J A

    2010-08-01

    In Experiment 1, studies were conducted to apply the transvaginal ultrasound guided ovum pick-up (OPU) technique in dromedary camels after their ovarian super-stimulation and in vivo oocyte maturation. In Experiment 2, the developmental potential of two commonly used oocyte types, i.e., in vivo matured oocytes collected by OPU and abattoir derived in vitro-matured oocytes was compared after their chemical activation. In Experiment 3, developmental competence of oocytes collected from super-stimulated camels by OPU, matured either in vivo or in vitro, was compared after their chemical activation. Mature female dromedary camels super-stimulated with a combination of eCG and pFSH were given an injection of 20 microg of the GnRH analogue, buserelin 24, 26, or 28 h before the scheduled OPU. For collection of cumulus oocyte complexes (COCs) the transducer was guided through the vulva into the cranial most portion of the vagina and 17-gauge, 55 cm single-lumen needle was placed in the needle guide of the ultrasound probe and advanced through the vaginal fornix and into the follicle. Follicular fluid was aspirated using a regulated vacuum pump into tubes containing embryo-flushing media. Aspirates were searched for COCs using a stereomicroscope, and they were then denuded of cumulus cells by hyaluronidase and repeated pipetting. The oocytes were classified as mature (with a visible polar body), immature (with no visible polar body), activated (with divided or fragmented ooplasm) and others (degenerated and abnormal). Overall an average of 12.12 +/- 7.9 COCs were aspirated per animal with an oocyte recovery rate from the aspirated follicles of about 77%. The majority (> 90%) of the collected COCs by OPU were with loose and expanded cumulus cells. The proportion of matured oocytes obtained at 28-29 h (91.2 +/- 4.1) and 26-27 h (82.1 +/- 3.4) were higher (P ultrasound guided transvaginal ovum pick-up from super-stimulated dromedary camels 26-28 h after GnRH administration

  14. Redução da primeira dose de GnRH em vacas holandesas de alta produção sincronizadas com Ovsynch ou Heatsynch

    Directory of Open Access Journals (Sweden)

    Flávio Aragon Lima

    2010-04-01

    Full Text Available The objective of this study was to evaluate the effect of treatment with 10 or 20 µg of GnRH and type of FTAI protocols (Ovsynch and Heatsynch on pregnancy rate of lactating dairy cows submitted to the synchronization at FTAI (n = 581. The animals were distributed among four treatments, allocated factorial design 2x2: Treat 1- Ovsynch (20 µg GnRH on D0; PGF on D7; 10 µg GnRH on D9 and FTAI on D10; n = 141, Treat 2- ½ Ovsynch (10 µg GnRH on D0; PGF on D7; 10 µg GnRH on D9 and FTAI on D10; n = 159, Treat 3- Heatsynch (20 µg GnRH on D0; PGF on D7; 1 mg EB on D8 and FTAI on D10; n = 147 and Treat 4- ½ Heatsynch (10 µg GnRH on D0; PGF on D7; 1 mg EB on D8 and FTAI on D10; n = 134. The Group Ovsynch (Treat 1 and 2 presented greater pregnancy rate than Group Heatsynch (Treat 3 and 4 at 28 days (45.7% (137/300 and 39.9% (112/281, respectively; P = 0.07 and at 56 days of gestation (41.0% (123/300 and 34.2% (96/281, respectively; P = 0.06. There were no statistical difference (P >; 0.10 on pregnancy rate at 28 (44.4% (128/288 vs 41.3% (121/293; P = 0.50 and 56 days (38.2% (110/288 vs 37.2% (109/293; P = 0.68 between the dosages of the GnRH. The pregnancies losses (between 28 and 56 days were not different between the FTAI protocols and GnRH dosage (P >; 0.10. We concluded that the Ovsynch protocol presented greater pregnancy rate at FTAI than Heatsynch protocol and the administration of 10 µg of buserelin Acetate, at the beginning of these protocols did not decrease the efficiency of FTAI protocols in high-yielding Holstein cows.

  15. Oestrus synchronization with short-term and long-term progestagen treatments in goats: the use of GnRH prior to short-term progestagen treatment

    Directory of Open Access Journals (Sweden)

    Cafer Tayyar Ateş

    2010-02-01

    Full Text Available The aim of the present study was to determine the efficacy of the synchronization of oestrus using short- and long-term progestagen treatments in Hair goats at the onset of the breeding season, and to evaluate the effect of the exogenous GnRH administration immediately prior to short-term progestagen treatment on the reproductive performance. A total of 75 Hair goats, aged 2.5-5 years-old were used in this experiment. Goats were divided equally into three groups (n=25 per group. Animals in LT-FGA (long-term progestagen treatment, ST-FGA (short-term progestagen treatment and Gn-ST-FGA (GnRH-short-term progestagen treatment groups received an intravaginal sponge (day 0 containing 30 mg fluorogestone acetate (FGA for 14, 8 and 8 days, respectively, plus 75 μg cloprostenol i.m. 24 h before sponge removal and 400 I.U. equine chorionic gonadotrophin (eCG i.m. at the time of sponge removal. In addition, the goats in the Gn-ST-FGA group received 10.5 μg busereline acetate i.m. at the time of sponge insertion (day 0. Oestrus response for all treatment groups was 100%. The mean interval from sponge removal and the onset of oestrus for the LT-FGA, ST-FGA and Gn-ST-FGA groups was 28.0±1.0 h, 28.83±1.1 h and 33.1±2.0 h, respectively. No significant difference in onset of oestrus among groups was recorded. The pregnancy rate, kidding rate, multiple kidding rates and litter size were 72.0, 61.1, 45.5% and 1.6 in the LT-FGA, 70.8, 76.5, 69.2% and 1.8 in the ST-FGA and 58.3, 78.6, 63.6% and 1.6 in the Gn-ST-FGA groups, respectively. The pregnancy rates were similar in the LT-FGA (72.0% and ST-FGA (70.8%. However, the kidding rate, multiple kidding rates and litter size were numerically higher in the ST-FGA (76.5%, 69.2% and 1.8, respectively group than in the LT-FGA (61.1%, 45.5% and 1.6, respectively group. Although not statistically different, pregnancy rate and litter size was lower in the Gn-ST-FGA group (58.3% and 1.6, respectively compared with the ST